Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study - Summary - MDSpire
Advertisement
Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study
To investigate the efficacy and safety of DEB-TACE compared to cTACE in treating elderly patients with colorectal cancer liver metastases (CRCLM).
Key Findings:
No significant differences in baseline characteristics between DEB-TACE and cTACE groups.
DEB-TACE showed a higher tendency for complete response rate (10.0% vs. 4.3%) and objective response rate (55.0% vs. 30.4%), but these differences were not statistically significant.
PFS was longer in the DEB-TACE group (11.7 months) compared to cTACE (6.1 months, P = 0.013).
OS showed a tendency to be longer in DEB-TACE (21.6 months) compared to cTACE (16.3 months, P = 0.076), but not statistically significant.
Incidence of AEs was similar between both groups.
Interpretation:
DEB-TACE may provide a longer PFS in elderly CRCLM patients compared to cTACE, though OS differences were not statistically significant, suggesting a need for further research.
Limitations:
Retrospective design may introduce bias.
Small sample size limits generalizability.
Lack of randomization between treatment groups.
Potential confounding factors not controlled for.
Conclusion:
DEB-TACE can be considered an optional choice for the treatment of elderly CRCLM patients, warranting further investigation into its long-term benefits.
